Back to the Top
For a drug-drug interaction study, the strong CYP 3A4 inhibitor (perpetrator) exposure should be
long enough to cover the AUCo-inf of the substrate (in this case about 60 days as its half-life is
10 days). This would mean 60 days of exposure to a strong CYP 3A4 inhibitor in normal volunteers
which we’d like to obviously avoid. What type of study design could be done to circumvent this.
I look forward to your comments.
Martine Allard, RPh, PhD
|
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@lists.ucdenver.edu with "Study design question for Long half-life CYP 3A4 substrate in a drug-drug interaction study" as the subject |
Copyright 1995-2014 David W. A. Bourne (david@boomer.org)